CJC-1295 with DAC – 5mg (10-Vial Research Kit)

CJC-1295 & Ipamorelin is a dual-pathway research peptide blend combining a growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R) agonist. This formulation is widely studied for its potential synergistic stimulation of endogenous growth hormone (GH) release in controlled laboratory environments.
 
CJC-1295 (No-DAC) works by activating GHRH receptors in the pituitary, supporting natural GH signaling without extended binding activity. Ipamorelin selectively stimulates ghrelin receptors (GHS-R), offering targeted GH pathway activation with minimal interaction with cortisol or prolactin pathways in research models.
 
When combined, these peptides allow researchers to explore pulsatile GH release through complementary mechanisms, making the blend a popular choice in endocrine and metabolic research.
 
Research Applications
This peptide blend is studied for its potential role in:
Investigating growth hormone release via dual receptor pathways
Exploring endocrine signaling and GH pulse dynamics
Supporting studies on cellular repair and recovery mechanisms
Assessing metabolic and body composition–related pathways
Evaluating GH modulation without prolonged peptide exposure, unlike DAC-modified analogues
 
Reconstitution Instructions
Reconstitute with Bacteriostatic (BAC) water before use.
Refrigerate after reconstitution and handle under sterile laboratory conditions.
Use our Peptide Calculator for accurate preparation.
For laboratory research use only. Not for human consumption.